Abbvie Inc.

Renee Miller

Lorenzo Benatuil

Jacqueline G Bixby

Ravi Chari

Chengbin Wu

Dominic J Ambrosi

Feng Dong

Emma Fung

Liangjun Lu

Susan E Lacy

Preethi Krishnan

Meha Chhaya

Tatyana Dekhtyar

Axel Hernandez, Jr

Chung-ming Hsieh

Gautam Sahu

Federico Mensa

Teresa (Iok-Chan) Ng

Jing Min

Sarah J Heighton

The present disclosure provides anti-&#x3b1;4&#x3b2;7 antibodies that bind human &#x3b1;4&#x3b2;7, their methods of making, and their uses to treat patients with HIV infection.

Anti-alpha-4-beta-7 antibodies

The disclosure provides binding proteins that specifically bind to IL-1&#x3b1; and IL-1&#x3b2;. These binding proteins can be organized into DVD-Igs. These proteins can be used to modulate the activity of IL-1&#x3b1; and/or IL-1&#x3b2; and can be used for the treatment immunological diseases such as rheumatoid arthritis, osteoarthritis, psoriasis, multiple sclerosis, and other autoimmune diseases. In addition, their uses in the amelioration and/or treatment of pain in an individual suffering from a disease or disorder associated with IL-1 accumulation.

IL-1 binding proteins

The present invention describes IL-1&#x3b2; binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind IL-1&#x3b2;. Binding proteins of the invention have high affinity for IL-1&#x3b2; and neutralize IL-1&#x3b2; activity. A binding protein of the invention can be a full-length antibody or an IL-1&#x3b2;-binding portion thereof. Methods of making and methods of using the binding proteins of the invention are also described. The IL-1&#x3b2; binding proteins of the invention are useful for detecting IL-1&#x3b2; and for inhibiting IL-1&#x3b2; activity, including in a human subject suffering from a disease or disorder in which IL-1&#x3b2; activity is detrimental.

Growing community of inventors

N. Grosvenordale, CT, United States of America

Renee Miller